Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Novacyt ( (FR:ALNOV) ) has shared an announcement.
Novacyt has expanded its precision medicine portfolio with the launch of the Yourgene Insight DPYD assay, a pharmacogenetic test designed to improve the safety of chemotherapy involving 5-fluorouracil and related fluoropyrimidines. The new assay identifies cancer patients with DPD deficiency, enabling clinicians to tailor treatment and reduce severe or potentially fatal side effects.
The updated test increases detectable DPYD variants from six to 19, including 14 recommended under recently revised international guidelines, underscoring Novacyt’s responsiveness to evolving clinical standards. Initially released for research use only, with further regulatory approvals planned, the assay maintains the existing workflow and same-day turnaround, strengthening the company’s market position in personalised oncology and demonstrating tangible returns from its ongoing R&D investment.
More about Novacyt
Novacyt S.A. is an international molecular diagnostics company focused on delivering genomic medicine through a broad portfolio of molecular assays, instruments and integrated workflows. It serves multiple sectors including human and animal health and environmental testing, with core offerings in reproductive health, precision medicine and infectious disease diagnostics.
The group operates across three segments—clinical diagnostics, instrumentation and research-use-only services—providing end-to-end solutions from sample to result for global health organisations and the life sciences industry. Headquartered in Le Vésinet, France, with offices in the UK, Singapore, the US and Canada, Novacyt has a presence in over 65 countries and is dual-listed in Paris and on London’s AIM market.
Learn more about ALNOV stock on TipRanks’ Stock Analysis page.